Treatment of global cardiovascular risk with fixed-dose ASCOT combination: atorvastatin, perindopril, and amlodipine

A fixed combination product, composed of atorvastatin, perindopril and amlodipine, such as that used in the ASCOT study, has just been marketed by the Servier company under the trade name LIPERTANCE®. This provides us the opportunity to recall the usefulness of this double approach targeting both high blood pressure and high cholesterol levels in cardiovascular prevention. The ASCOT study has definitely proven the remarkable cardiovascular benefit of this combination in primary prevention for hypertensive patients with moderately-high cholesterol levels. Key Words cardiovascular disease, cardiovascular prevention, hypercholesterolemia, high blood pressure, LDL cholesterol, atherosclerosis